CD30 is variably expressed in DLBCL, at a frequency of up to 60% depending on cut-off value [4, 114], but unexpectedly, some studies have suggested that the response to brentuximab vedotin treatment does not correlate with CD30 expression [115]. Here, TNFRSF8 is linked to diffuse large B-cell lymphoma.